DENTSPLY SIRONA (NASDAQ:XRAY) Shares Cross Above 50-Day Moving Average – What’s Next?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $9.68 and traded as high as $9.96. DENTSPLY SIRONA shares last traded at $9.90, with a volume of 6,060,465 shares.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on XRAY shares. Barclays increased their target price on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday, August 24th. BMO Capital Markets cut their price target on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research note on Thursday, September 17th. Piper Sandler reduced their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Friday, October 9th. Mizuho lowered their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, October 22nd. Finally, Leerink Partners lowered their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $12.62.

DENTSPLY SIRONA Trading Up 3.9%

The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. The stock’s 50 day moving average is $9.68 and its 200-day moving average is $11.33. The company has a market cap of $1.97 billion, a PE ratio of -3.60, a P/E/G ratio of 1.21 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. During the same period last year, the company posted $0.52 EPS. The business’s revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.39 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in XRAY. Paradigm Capital Management Inc. NY purchased a new stake in DENTSPLY SIRONA during the second quarter valued at approximately $39,775,000. BlackRock Inc. bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at approximately $283,405,000. The Manufacturers Life Insurance Company purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $1,956,000. Bank of New York Mellon Corp purchased a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $16,408,000. Finally, Edmond DE Rothschild Holding S.A. bought a new position in shares of DENTSPLY SIRONA during the 2nd quarter valued at approximately $47,780,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.